Vocational rehabilitation programs for individuals with chronic arthritis

Current Opinion in Rheumatology

Volumn 21, Issue 2, 2009, Pages 183-188

  Vliet Vlieland, Theodora P M ^a   De Buck, Petronella D M ^a   Van Den Hout, Wilbert B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Economic evaluation; Osteoarthritis; Vocational rehabilitation; Work disability

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABSENTEEISM; CHRONIC ARTHRITIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; HUMAN; MEDICAL LEAVE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; TREATMENT OUTCOME; VOCATIONAL REHABILITATION;

EID: 62349115528     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328324e6eb     Document Type: Review

References (45)

1. Hammond A. Rehabilitation in musculoskeletal diseases. Best Pract Res Clin Rheumatol 2008; 22:435-449.
2. Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr Opin Rheumatol 2002; 14:121-126.
3. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007; 19:91-96.
4. de Buck PDM, Schoones JW, Allaire SH, Vliet Vlieland TPM. Vocational rehabilitation in patients with chronic rheumatic diseases: a systematic literature review. Semin Arthritis Rheum 2002; 32:196-203.
5. Varekamp I, Verbeek JHAM, van Dijk FJH. How can we help employees with chronic diseases to stay at work? A review of interventions aimed at job retention and based on an empowerment perspective. Int Arch Occup Environ Health 2006; 80:87-97.
6. Gobelet C, Luthi F, Al-Khodairy AT, Chamberlain MA. Work in inflammatory and degenerative joint diseases. Disabil Rehabil 2007; 29:1331-1339.
7. Allaire SH. Update on work disability in rheumatic diseases. Curr Opin Rheumatol 2001; 13:93-98.
8. Allaire S, Wolfe F, Niu J, Lavalley MP. Contempory prevalence and incidence of work disability associated with rheumatoid arthritis. Arthritis Rheum 2008; 59:474-480. This large epidemiological study provides up-to-date prevalence rates of work disability in RA.
9. Eberhardt K, Larsson BM, Nived K, Lindqvist E. Work disability in rheumatoid arthritis: development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007; 34:481-487.
10. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006; 33 (Suppl 78):4-11.
11. Ward MM, Reveille JD, Learch TJ, et al. Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 2008; 59:497-503.
12. Marengo MF, Schneeberger EE, Citera G, Cocco JAM. Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 2008; 14 [Epub ahead of print].
13. Tam S-S, Chan K-Y, Li EK. The influence of illness and variables associated with functional limitations in Chinese patients with ankylosing spondylitis. J Rheumatol 2007; 34:1032-1039.
14. Rkain H, Allali F, Bentalha A, et al. Socioeconomic impact of ankylosing spondylitis in Morocco. Clin Rheumatol 2007; 26:2081-2088.
15. Allaire S. Is work disability associated with systemic lupus erythematosus modifiable? [editorial]. J Rheumatol 2008; 35:953-955.
16. Yelin E, Trupin L, Katz P, et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum 2007; 57:56-63. Large cohort study on the epidemiology of work disability among patients with SLE.
17. Bultink IEM, Turkstra F, Dijkmans BAC, Voskuyl AE. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol 2008; 35:1053-1057.
18. Utset TO, Chohan S, Booth SA, et al. Correlates of formal work disability in an urban university systemic lupus erythematosus practice. J Rheumatol 2008; 35:1046-1052.
19. Sandqvist G, Eklund M. Daily occupations: performance, satisfaction and time use, and relations with well being in women with limited systemic sclerosis. Disabil Rehabil 2008; 30:27-35.
20. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21 (5 Suppl 31):S71-S74.
21. Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004; 51:488-497.
22. Zirkzee EJ, Sneep AC, de Buck PD, et al. Sick leave and work disability in patients with early arthritis. Clin Rheumatol 2008; 27:11-19.
23. Allaire SH. What work changes do people with arthritis make to preserve employment, and are such changes effective? [editorial]. Arthritis Rheum 2004; 51:909-916.
24. Gignac MAM, Sutton D, Badley EM. Arthritis symptoms, the work environment, and the future: measuring perceived job strain among employed persons with arthritis. Arthritis Rheum 2007; 57:738-747.
25. Lacaille D, White MA, Backman CL, Gignac MAM. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients'perspective. Arthritis Rheum 2007; 57:1269-1279.
26. Puolakka K, Kautiainen H, Möttönen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drigs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55-62.
27. Puolakka K, Kautiainen H, Möttönen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005; 64:130-133.
28. Laas K, Peltomaa R, Kautiainen H. Pharmcacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006; 65:924-928.
29. Listing J, Brandt J, Rudwaleit M, et al. Impact of antitumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004; 63:1670-1672.
30. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of antitumor necrosis factor on work disability. J Rheumatol 2007; 34:2211-2217. In this large retrospective cohort study including 3886 patients with RA, no protective effect of anti-TNF therapy on work disability was found. After adjustment for demographics, RA severity, and comorbidity the RR for work disability in patients receiving anti-TNF (receipt of US social security disability benefit) in patients treated with anti-TNF was 1.2 (95% CI 0.8-1.8), whereas the RR for self-reported work disability was 1.6 (1.1-2.4).
31. Verstappen SMM, Jacobs JWG, Hyrich KL Effect of antitumor necrosis factor on work disability [editorial]. J Rheumatol 2007; 34:2126-2128.
32. Allaire S, Wolfe F, Niu J, et al. Evaluation of the effect of antitumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum 2008; 59:1082-1089. Using a nested case-control design it was found in 953 patients with RA that anti-TNF use did not protect against any or RA attributed employment loss (OR 0.9, 95% CI 0.5-1.5). However, a protective effect was found in a subgroup of users with RA and a disease duration of less than 11 years (OR 0.4, 95% CI 0.2-0.9).
33. Van den Hout WB, Goekoop-Ruiterman Y, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent onset rheumatoid arthritis. Arthritis Rheum (in press). Study in 508 patients with recent-onset RA, comparing initial monotherapy to combinations of DMARDS, corticosteroids, or TNF antagonists. Initial biologic therapy resulted in better quality of life. Depending on the extent to which productivity was valued, the associated treatment costs were either too high or largely compensated by savings on productivity.
34. Keat AC, Gaffney K, Gilbert AK, et al. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology 2008; 47:481-483. An observational study showing in 65 patients with AS of working age that after receiving anti-TNF therapy the number of patients working full time increased, whereas the number of unemployed patients decreased.
35. Allaire SH, Li W, LaValley MP. Reduction of job loss in persons with rheumatic diseases receiving vocational rehabilitation: a randomized controlled trial. Arthritis Rheum 2003; 48:3212-3218.
36. de Buck PDM, le Cessie S, van den Hout WB, et al. Randomized comparison of a multidisciplinary job-retention vocational rehabilitation program with usual outpatient care in patients with chronic arthritis at risk for job loss. Arthritis Rheum 2005; 53:682-690.
37. Nordmark B, Blomqvist P, Andersson B, et al. A two-year follow-up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational experience from the FIN-RACo trial. Scand J Rheumatol 2007; 36:270-277.
38. Abásolo L, Blanco M, BAchiller J, et al. A health system program to reduce work disability related to musculoskeletal disorders. Ann Intern Med 2005; 143:404-414.
39. Abásolo L, Carmona L, Hernández-García C, et al. Musculoskeletal work disability for clinicians: time course and effectiveness of a specialized intervention program by diagnosis. Arthritis Rheum 2007; 57:335-342. This randomized controlled trial shows that in 187 patients with inflammatory arthritis who began sick leave temporary work disability episodes were significantly shorter in a group who underwent a standardized intervention by a rheumatologist (median duration of sick leave 18 days, 25-75th percentile 8-61) than in the control group (median duration 41 days, 25-75th percentile 15-109) over 2 years).
40. Abásolo L, Carmona L, Lajas C, et al. Prognostic factors in short-term disability due to musculoskeletal disorders. Arthritis Rheum 2008; 59: 489-496.
41. Fleten N, Johnsen R. Reducing sick leave by minimal postal intervention: a randomised, controlled intervention study. Occup Environ Med 2006; 63:676-682.
42. Gilworth G, Chamberlain MA, Harvey A, et al. Development of a work instability scale for rheumatoid arthritis. Arthritis Rheum 2003; 49:349-354.
43. Puolakka K, Kautiainen H, Motionen T, et al. Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: support. Scand J Rheumatol 2006; 35:7-14.
44. Van den Hout WB, de Buck PD, Vliet Vlieland TP. Cost-utility analysis of a multidisciplinary job retention vocational rehabilitation program in patients with chronic arthritis at risk of job loss. Arthritis Rheum 2007; 57:778-786. Study in 121 with chronic rheumatic diseases at risk of job loss, comparing a multidisciplinary job retention vocational rehabilitation program with usual care. Apart from the vocational rehabilitation program costs, no differences were found in healthcare consumption, productivity, or quality-adjusted life years. From a societal perspective, it remained unclear whether the program reduced or increased total costs.
45. Kanavos P, Trueman P, Bosilevac A. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom. Int J Technol Assess Healthcare 2000; 16:1179-1192.